Fennec Pharmaceuticals has rebounded to near 52-week highs after PEDMARK drove the business to profitability, easing dilution fears. Despite 78% Y/Y net sales growth and a positive Q2 net income, the ...
Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results